Trial Profile
A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms HAVEN 5
- Sponsors Roche
- 02 Jun 2022 Planned primary completion date changed from 31 May 2022 to 3 Aug 2022.
- 18 Mar 2022 Planned End Date changed from 8 Nov 2022 to 31 May 2025.
- 12 Nov 2021 Planned primary completion date changed from 19 Nov 2021 to 31 May 2022.